Byhealth (300146) Q4 2024 earnings summary

Executive summary

• 2024 saw a significant downturn in performance due to intensified competition, shifting consumer channels, and delays in core product upgrades, resulting in a sharp year-over-year decline in revenue and profit.

• The company maintained its leadership in China's VDS market with a 9.3% share, despite industry headwinds and a 20% drop in offline pharmacy sales.

• Strategic focus shifted to high-quality, sustainable growth, digital transformation, and international expansion, with a continued commitment to scientific innovation and product quality.

Financial highlights

• Operating income for 2024 was ¥6.84 billion, down 27.3% year-over-year; net profit attributable to shareholders was ¥653 million, down 62.62%.

• Gross margin for main business was 67.43%, down 1.92 percentage points year-over-year.

• Net cash flow from operating activities dropped 66.56% to ¥686 million.

• Basic EPS was ¥0.39, down 62.14% year-over-year.

• Total assets at year-end were ¥14.28 billion, a 5.42% decrease from the prior year.

Outlook and guidance

• 2025 will focus on operational quality, innovation in core categories, digitalization, and international market expansion.

• Launch of the first independently developed OTC product and further investment in anti-aging and precision nutrition research are planned.

• The company aims to balance growth between offline and online channels, with targeted investments in high-value e-commerce and international business.